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Suprihati * 
ABSTRAK 
Background: Allergic disease including allergic rhinitis (AR) is dominated by Th2 responses with increased production of IL-4 and 
inhibition of IFN- production. BCG vaccination induced IL-12 production which promotes Th0 to Th1 shift and stimulates IFN- 
production. The aim of this study is to determine whether BCG vaccination prior specific immunotherapy (SIT) could increase initial 
phase of SIT responses measured by decreasing IL-4/IFN- ratio’s and AR total symptom score (TSS). 
Method: This study was carried out by a randomized controlled trial. A total of 84 patients with moderate to severe persistent AR 
were randomized and assigned into 4 treatment groups (BCG solvent, BCG vaccination, SIT, and BCG vaccination prior SIT).              
A subcutaneous SIT was given using mixed house dust mite extract (D pteronyssinus and D farinae, 50/50), while BCG vaccination 
was given by intracutaneous injection. Clinical symptoms and concentrations of IL-4 and IFN-γ were measured by PHA stimulated 
fresh whole blood culture, before and after 8 weeks of SIT.   
Result: There were no significance difference between the concentrations of IL-4 and IFN-γ, and their ratio in all four groups. 
However, there is a significant lower IL-4/IFN- ratio in the group with pretreatment of BCG than SIT (p=0.024), while during the 
initial phase, AR symptoms in patients who received BCG prior SIT is significantly lower than SIT (p=0.027). 
Conclusion: This study demonstrates that BCG vaccination prior to SIT treatment could increase initial phase of SIT responses in 
persistent allergic rhinitis without additional adverse effects.   
Keywords: BCG vaccination, specific immunotherapy, allergic rhinitis 
ABSTRACT  
Efek vaksinasi BCG pre imunoterapi spesifik terhadap rasio IL-4/IFN-γ dan skor gejala total rinitis pada rinitis alergi persisten 
Latar belakang: Pada penyakit alergi, termasuk rinitis alergi (RA) didominasi oleh respon Th2 yang meningkatkan produksi IL-4 
yang kemudian menghambat produksi IFN-. Vaksinasi BCG memicu produksi IL-12 yang menyebabkan pergeseran Th0 ke Th1 dan 
menginduksi produksi IFN-. Penelitian ini bertujuan untuk membuktikan bahwa vaksinasi BCG pre imunoterapi spesifik (IT) dapat 
meningkatkan respon IT spesifik selama fase inisial dengan mengukur rasio IL-4/IFN- dan skor gejala total rinitis alergi.  
Metode: Sebanyak 84 pasien RA persisten sedang–berat yang memenuhi kriteria penelitian dilakukan randomisasi ke dalam 4 
kelompok pengobatan (pelarut BCG sebagai kontrol, vaksinasi BCG, IT dan vaksinasi BCG pre IT). Imunoterapi spesifik disuntikkan 
sub kutan 2 kali seminggu selama 8 minggu dengan ekstrak campuran (D pteronyssinus dan D farinae, 50/50). Vaksinasi BCG 
diberikan secara intra kutan. Konsentrasi IL-4 dan IFN-γ diukur dari kultur darah segar yang distimulasi  phytohemaglutinin (PHA). 
Rasio IL-4/IFN-  dan skor gejala total RA dianalisis sebelum dan setelah IT spesifik 8 minggu.   
Hasil: Tidak terdapat perbedaan bermakna antara konsentrasi IL-4 dan IFN-γ serta rasionya sebelum dan sesudah terapi pada 
semua kelompok pengobatan, tetapi rasio IL-4/IFN- pada kelompok BCG pre IT pada akhir fase inisial IT lebih rendah dibanding 
kelompok IT (p=0,024). Selama fase inisial IT, skor total gejala RA pada kelompok BCG pre IT juga lebih rendah secara bermakna 
dibanding kelompok IT (p=0,027).    
Simpulan: Penelitian ini menunjukkan bahwa vaksinasi BCG pre IT meningkatkan respon fase inisial IT spesifik pada penderita 
rhinitis alergi persisten tanpa efek samping yang berarti. 
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INTRODUCTION 
Allergic disease is dominated by Th2 responses with 
increased production of IL-4 resulting in inhibition of 
IFN- production and induction of IgE production.1,2  
Allergic rhinitis (AR) may interfere the health status, 
impair quality of life and need a high cost of treatment. 
AR prevalence in USA was 14.2%, while in Semarang, 
Indonesia, the prevalence among 13-14 year old 
students was 18.6%.3,4 
Specific immunotherapy (SIT) is an effective treatment 
for AR and has a long residual effects after 
discontinuation.5 The effects of SIT consist of the shift 
of Th2 to Th1 cytokine production, decrease of the 
specific IgE and nasal mucosa eosinophils and increase 
of IgG4 resulting in the decrease of AR symptoms.
6 It is 
recommended that patients with a moderate to severe 
persistent AR and are resistant to pharmacologic 
treatment need a specific immunotherapy.7    
For the last decades, atopic diseases have been 
increased in the developed countries. The increase 
might be due to environmental changes, diet factors, the 
way of life and vaccination programs. There was an 
inverse association between tuberculin positive response 
and the low prevalence of atopic diseases in Japan.8 
BCG vaccination decreases an atopic disease since BCG 
vaccine is a Th1 inducer for the production of 
endogenous IL-12 cytokine, thus in ducing the IFN- 
production. IL-12 cytokine also stimulates Th1 and NK 
cells to produce IFN-.9 An intranasal BCG infection 
showed a suppressive effect on eosinophils 
accumulation within the lung, which is the most 
pronounced suppressive effect obtained when BCG is 
given one week before the allergen challenge.10 The 
nose and the lung are components of the respiratory 
tract, however, the effect of BCG in the nasal mucous 
membrane has not been determined. To test this 
hypothesis, we have conducted a study to determine 
production of IL-4 and IFN-γ, IL-4/IFN- ratio, and 
total symptoms score (TSS) in AR patients given BCG 
vaccination prior to specific immunotherapy compared 
to the end of initial phase of specific immunotherapy 
(SIT).   
METHOD 
This is a randomized controlled study. Patients with 
moderate to severe persistent AR, aged from 15-50 
years old with a positive (+++) skin prick test results to 
house dust mite allergens, either dermatophagoides 
pteronyssinus or dermatophagoides farinae, were 
enrolled into the study.  
The patients were excluded when taken antihistamine 
and anti-inflammatory drugs within 72 hours, systemic 
or topical corticosteroid within 2 weeks or have depot 
corticosteroid within 8 weeks. Patients who were 
pregnant or lactating, presence of sinusitis with or 
without nasal polyps, history of receiving SIT, severe 
allergic manifestations, cardiac abnormality, patients 
who took β-blocker or antihypertensive medication, 
pulmonary tuberculosis or Mantoux test more than 10 
mm diameter were excluded from this study. All 
patients gave their informed consent and the study was 
approved by the hospital/faculty ethical committee. 
Eligible patients were randomly assigned into 4 groups.  
First group received intracutaneous BCG solvent 
(Group I, the control group), the second group received 
intracutaneous BCG vaccination (Group II), the third 
group received a specific immunotherapy (Group III) 
and the forth group received BCG vaccination prior to 
the specific immunotherapy (Group IV). Mantoux test 
was done in the patients selection using PPD RT 23. 
Patients who have lost of follow-up for more than 4 
weeks of treatment were considered as the drop-out 
cases. 
The dose of BCG solvent was 0.1 ml and the same 
volume for BCG vaccine (2 x 105 CFU, Paris strain No. 
1172 P2). Initial phase treatment of SIT comprised 
dermatophagoides mix allergens (dermatophagoides  
pteronyssinus and dermatophagoides farinae, 50/50) 
extract allergen (ALK-AbelloR) with varying 
concentrations of 1, 10, 100 and 1,000 STU/ml, 
respectively.  Subcutaneous injection was given twice a 
week for initial dose phase (according to the 
manufacturers’ instruction) for up to 8 weeks.   
IL-4/IFN-γ ratio and AR total symptoms score (TSS) 
were determined in all study patients. IL-4 and IFN-γ 
were measured using phytohemaglutinin (PHA) 
stimulated fresh whole blood culture with compact 
human IL-4 and human IFN-γ ELISA Kit (PelikineR) at 
the Biotechnology Laboratory, the Faculty of Medicine, 
Diponegoro University. Whole blood culture was used 
to anticipate a very low level of cytokines in the serum. 
The advantage of using a whole blood culture were a 
short incubation time, simple and similar to the in vivo 
conditions.11 PHA stimulation was chosen because at the 
preliminary study gave the best result compared to LPS 
and mite antigen. The sensitivity of the test was 0.2 
pg/ml for IL-4 and 1 pg/ml for IFN-γ.  
The major allergic rhinitis symptoms included sneezing, 
rhinorhea, nasal obstruction and nasal itching which 
were measured subjectively using a 4-point scale by 
diary card. Scale 0 (zero) is when there was no allergic 
rhinitis symptoms, scale 1 (mild) when allergic rhinitis 
symptoms do not disturb patient’s activity, scale 2 
(moderate) when allergic rhinitis symptoms disturb 
patient’s activity/sleep and scale 3 (severe) when 
allergic rhinitis symptoms disturbed the patient’s 
activity/sleep.12    
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The sample size was calculated based on 50% of 
reduced TSS score in BCG+SIT as compared to SIT 
along group, 0.80 power of the study and significant 
level of 0.05. To compare patient’s characteristic 
between treatment group were analyzed by Chi square 
test for nominal data, Kruskal Wallis test for normally 
distributed data and using analysis of variants for not 
normally distributed data. Since the data of IL-4, IFN-γ 
cytokines and their ratio were not normally distributed, 
log transformation was used for analyzing these data. 
The difference between cytokines (IL-4 and IFN-γ) 
levels before and after treatment were analyzed by 
paired t-test. The difference of IL-4/IFN-γ ratio and  
allergic rhinitis TTS before and after treatment were  
determined by Wilcoxon Signed Ranks tests. At the end 
of treatment, the comparison of IL-4/IFN-γ ratio and  
allergic rhinitis TTS between each treatment group were 
determined by Mann Whitney U test.   
Since AR TSS was evaluated everyday during 8 weeks, 
the Area Under the Curve (AUC) NCSS 2000– 
PASS200 program was used to compare the AUC 
during SIT and BCG prior SIT groups. MANOVA test 
was used to determine whether sex, age, duration of 
illness and allergic family history influenced the 
treatment results.   
RESULTS 
Patients sampling were done during July 2004 to 
December 2005. A total of 84 patients have been 
recruited in this study and 73 (86.9%) patients have 
completed the study. However, analysis of the data was 
based on 55 cases who had a complete set of results of 
IL-4 and IFN-γ measurements, and symptom score 
records before and after the treatment. It was found that 
sex, age, allergic family history, duration of AR, IFN-γ 
level and IL-4/IFN-γ ratio, AR total symptom score 
before treatment were comparable between groups, 
except IL-4 cytokine (Table 1).    
There were changes in IL-4 and IFN- production  
during the study, however, there was no significant 
difference between IL-4, IFN- and their ratio before 
and after treatment in all groups  of treatment (Table 2).  
At the end of the study, however, IL-4/IFN- ratio 
decreased only in BCG prior SIT group and it was 
significantly lower than IL-4/IFN- ratio in SIT group   
(Table 3). 
At the end of the study, the significant difference of AR  
TSS was found between: a) control (group I) and  BCG 
groups (group II) (p=0.034), b) control (group I) and 
SIT groups (group III) (p=0.02), c) control (group I) and  
BCG prior SIT groups (group IV) (p=0.009) and BCG 
(II) and SIT groups (group III) (p=0.049). Allergic 
rhinitis TSS between SIT and BCG prior SIT groups 
was not significant different, however, during the period 
of study, using AUC analysis, the result showed that the 
AUC during SIT was significantly larger than the AUC 
during BCG prior SIT (p=0.027), and the difference was 
came from the nasal obstruction symptoms (p=0.005)  
(Fig. 1a, 1b, 1c and 1d). From the MANOVA test, it 
showed that age (p=0.167), sex (p=0.711) duration of 
rhinitis (p=0.190) and allergic family history (p=0.9) do 
not influence the treatment results.                 
Table 1.  Sex, age, duration of illness, family history of allergy, median TSS, median nasal mucosa eosinophils, IL-4 and IFN-γ 
cytokines and their ratio before treatment 
Groups 
I 









BCG + SIT 
(n=21) 
p-value 
Sex      
Male 10 7 8 9 0.80* 
Female 11 14 13 12  
Age (years) 25 26.9 31.58 28 0.429**  
Family history of allergy      
Positive 15 8 12 11 0.188*  
Negative 6 13 9 10  
Duration of illness (months) 45.5 51 89 59 0.297** 
Median AR TSS 11 10 9 10 0.321** 
Median nasal mucosa eosinophil count 44 23 9 12 0.123** 
Median IL-4 (pg/ml) 14.5 16.21 61.52 40.37 0.017*** 
Median IFN-γ (pg/ml) 923.21 1,347.72 2,375.75 2,374.65 0.270*** 
IL-4/IFN-γ ratio 0.015 0.012 0.026 0.017 0.080**  
* Chi-square test, ** Kruskal Wallis test, *** Analysis of variants 
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Table 2.  Cytokine levels and their ratio before and after treatment (log transformation data) 








1.  IL-4     
 Before      14.15 16.21   61.52   40.37 
 After 19.44 30.63 56.88 37.70 
 p-value    0.434    0.109   0.835      0.917 
2.  IFN-γ     
 Before   923.21 1,347.72 2,375.75 2,374.65 
 After     1,170.31 1,159.04 1,585.26 2,659.50 
 p-value       0.780 0.728 0.256 0.821 
3.  IL-4/IFN-γ ratio     
 Before     0.015 0.012 0.026 0.017 
 After   0.017 0.026 0.036 0.014 
 p-value     0.878 0.124 0.906 0.826 
p-value (Willcoxon Signed Ranks test) 
  
 
Table 3.  Comparison of IL-4/IFN-γ ratio between groups at the end of the treatment (p value of Mann Whitney test) 
Group       BCG IT BCG + IT 
Control       p=0.048 p=0.015 p=0.292 
BCG        p=0.355 p=0.082 
IT         p=0.024 
 
        
Adverse effects of the treatments such as headache, 
itchy at the site of SIT injection and malaise were 
reported by some patients in each group, however,  
there was no significant difference between groups of 
treatment. Wheal and pustule formations at the site of 
injection were found in all patients who received BCG 
vaccination, however, it did not make patients 
discontinued their participation to the study.   
DISCUSSION 
At the end of the study, either IL-4 (increased 37.38%) 
or IFN- (increased 26.76%) production were increase 
in control group (group I), as well as for the IL-4/IFN- 
ratio. It means that BCG solvent injection did not  
change the domination of Th2 response in allergic 
rhinitis patients. In the BCG vaccination group (group 
II), IL-4/IFN- ratio has also increased at the end of the 
study which was due to the increase of IL-4 (88%) and 
decrease of IFN-γ (14%) production. It was reported 
that BCG vaccination could induce similar immune 
response to CD4
+ T cells and T-CD8
+ hsp-65 reactive 
cells in the spleen. After BCG vaccination, most 
stimulated cells were CD4l0 which produced IL-4 
besides IFN-γ.21 Furthermore, the highest T cell 
response to PPD was found 2 weeks after BCG 
vaccination and it was parallel with the maximum IFN-γ 
production, which has decreased after 8 weeks of BCG 
infection.10 
In the SIT group (group III), IL-4/IFN-γ ratio during 
escalating dose phase has increased (38.46%), and this 
finding is consistent with the previous study.13 The 
increase of IL-4/IFN-γ ratio in SIT group is caused by  
relatively higher production of IL-4 when compared to 
IFN-γ production. This phenomenon might be due to a 
low dose of allergen injection during escalating dose 
phase, in which dendritic cells involved in immunologic 
reactions are type-2 (DC-2) which would induce 
transcription factor for IL-4 production.14 It has been 
reported that in atopic patients the number of type-2 
dendritic cells (DC-2) increased significantly compared 
to non-atopic person.15 In fact, at the end of this study 
(after 8 weeks of treatment) in SIT group, either IL-4 
(decreased 7.54%) or IFN-γ (decreased 33.27%) has 
decreased and this might be caused by the role of 
regulatory T cells, since it was reported in semi-rush 
SIT that T cells produced IL-10 and TGF-β. Both 
cytokines are produced by CD4+.CD25+ T-cells and 
could be detected on day 7 of semi-rush SIT.16  
Regulatory T (Treg) cells produced IL-10 and TGF-β 
induced  by  dendritic cells during allergen injection and    
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         Mann-Whitney U test, AUC; p=0,112 
 
     Mann Whitney U test, AUC; p=0,09 
 
      Figure 1a.  Median score of itchy nose  
                    
  Figure 1b.  Median score of rhinorhea 
                                        
 
       Mann Whitney U test, AUC; p=0,138 
 
                   Mann Whitney U test, AUC; p=0,005 
                    
   Figure 1c.  Median score of sneezing 
                                       
       
              Figure 1d.  Median score of nasal obstruction 
                          
 
 
both cytokines suppressed the production of type-2 
cytokines (IL-4, IL-5) and type-1 cytokines (IFN-γ).17       
At the end of the study, IL-4/IFN-γ ratio in group IV 
(BCG vaccination prior SIT) has decreased and it was 
significantly lower than in SIT group (p=0.024), due to 
increased IFN-γ production and reduced IL-4 
production. This might be caused by intracellular 
infection of macrophages by BCG vaccine which then 
induced endogen IL-12 production.18 IL-12 is an 
important cytokine micro-environment for Th0 to Th1 
polarization and stimulates IFN-γ production by NK 
cells and Th1 cells.  Furthermore, the increase of IFN-γ 
production would suppress IL-4 production by Th2 
cells.19,20   
It has been reported that the median of IL-4/IFN-γ ratio 
in normal person was 1:117 (0.000854) but in AR 
patients was 1:4 (0.25) (p=0.00067).12 In allergic 
rhinitis, a treatment was considered successful in the 
immunological aspect when there is a decrease of IL-
4/IFN-γ ratio or a shift of cytokines production from Th2  
to Th1 response. Therefore, it can be concluded that 
BCG vaccination prior SIT plays an important role as an 
immunological inducer for cytokine type-1 response in 
AR patients during the initial phase dose of SIT. This 
result is consistent with the decrease of allergic rhinitis 
TSS, where the AUC of AR TSS during SIT was 
significantly larger than the AUC of AR TSS during 
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contributed by the improvements of nasal obstruction 
symptom. This immunological effect was not influenced 
by sex, age, duration of rhinitis and allergic family 
history of patients.  
CONCLUSION 
This study demonstrates that BCG vaccination prior SIT 
plays an important role as an immunological inducer for 
cytokine type-1 response in AR patients during the 
initial phase dose of SIT. It will result in decrease of IL-
4/IFN- ratio and improvement of AR TSS without 
additional adverse effects. 
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Figure 1a. Median  score of  itchy nose 
  
                    
                         Figure 1b.   Median score of rhinorhea 
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Mann Whitney U  test s  AUC  ; p= 0,138 
 
Mann Whitney U  test  AUC ; p= 0,005 
                    
                     Figure 1c.  Median score of sneezing 
                                       
       
                      Figure 1d.  Median score of nasal obstruction   
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